MabCure establishes research facilities on the campus of Hasselt University
02/04/2009
MabCure, N.V. (“MabCure”) a wholly owned subsidiary of MabCure Inc. (OTC BB:MBCI.OB) and LifeTechLimburg are pleased to announce the establishment of MabCure’s global research facilities on the research campus of Hasselt University where it will collaborate with the Biomedical Research Institute (“BIOMED”).
“MabCure aims to become a major player in the global cancer diagnostics field and we are privileged to be able to collaborate with BIOMED, which is well-known for its research activities in the field of chronic diseases including multiple sclerosis,” said Dr. Amnon Gonenne, MabCure’s President and CEO.
BIOMED Director, Professor Piet Stinissen, said, “We are privileged that MabCure chose to establish their research facilities at our institute. We are very impressed with their technology and their team and have full faith in their ability to make an impact on the field of cancer. We look forward to working together on joint projects for our mutual benefit.” MabCure and BIOMED have already voiced their intentions to cooperate on various joint projects, deploying MabCure’s technology for the generation of novel antibodies for various applications in the autoimmune disease field. Research activities at MabCure will be led by Dr. Elisha Orr, MabCure’s Chief Scientific Officer, an expert in molecular biology and immunology and the developer of MabCure’s technology and novel antibodies. The decision of MabCure to relocate to Limburg can partially be attributed to the support of LifeTechLimburg, your helping hand for life sciences and medical technology. “Being proceeded by the company Apitope only a few months ago, the relocation of MabCure once again demonstrates that Limburg holds important assets to attract foreign life science companies,” said Dr. Debora Dumont, Manager of LifeTechLimburg. The start-up of MabCure will be announced at BIOMEDICA, the key life sciences event in the Euregion Meuse-Rhine. Proceeded by two successful editions, BIOMEDICA 2009 is organised on 1-2 April in the Palais des Congrès in Liège, Belgium. BIOMEDICA is organised by the partnering organisations in the Euregion, including LifeTechLimburg. Marc Vandeput, deputy of economics affairs, said, “The province of Limburg acknowledges life sciences as a spearhead sector and financially supports BIOMEDICA via ‘Limburg Strong Brand.’ This allows a strong visibility of the Limburg life sciences sector at this event.” About MabCureMabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (Mabs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure initial goal is to develop its novel Mabs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website http://www.mabcure.com/. About BIOMED The Biomedical Research Institute (BIOMED) is a life sciences research institute of Hasselt University with a staff of 80 researchers, clinicians and technicians. The key research domains are focused on neuro-inflammatory and autoimmune diseases (multiple sclerosis and rheumatoid arthritis) and development of biosensors. http://www.biomed.uhasselt.be/ About LifeTechLimburg LifeTechLimburg, your helping hand for life sciences and medical technology, is the driving force behind the enforcement of the life sciences sector in the provincie of Limburg. LifeTechLimburg aims to stimulate innovation within existing life sciences companies and to create novel and attrack foreign companies with R&D activities in the field of biomedical life sciences.
http://www.lifetechlimburg.be/ Contact information:
Dr. Amnon Gonenne, President and CEO MabCure, email: amnon.gonenne@mabcure.com
Janet Vasquez, Public Relations, MabCure, 212-825-3210
James Carbonara Investor Relations, MabCure Inc, 212-825-3210 Dr. Debora Dumont, Manager LifeTechLimburg, GSM: +32 477 25 22 16, email: debora.dumont@uhasselt.be
|